Skip to main content

SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of Antidepressants


The class of serotonin and norepinephrine reuptake inhibitors (SNRIs) now comprises three medications: venlafaxine, milnacipran, and duloxetine. These drugs block the reuptake of both serotonin (5-HT) and norepinephrine with differing selectivity. Whereas milnacipran blocks 5-HT and norepinephrine reuptake with equal affinity, duloxetine has a 10-fold selectivity for 5-HT and venlafaxine a 30-fold selectivity for 5-HT. All three SNRIs are efficacious in treating a variety of anxiety disorders. There is no evidence for major differences between SNRIs and SSRIs in their efficacy in treating anxiety disorders. In contrast to SSRIs, which are generally ineffective in treating chronic pain, all three SNRIs seem to be helpful in relieving chronic pain associated with and independent of depression. Tolerability of an SNRI at therapeutic doses varies within the class. Although no direct comparative data are available, venlafaxine seems to be the least well-tolerated, combining serotonergic adverse effects (nausea, sexual dysfunction, withdrawal problems) with a dose-dependent cardiovascular phenomenon, principally hypertension. Duloxetine and milnacipran appear better tolerated and essentially devoid of cardiovascular toxicity.

Corresponding author
Please direct all correspondence to: Mike Briley, PhD, NeuroBiz Consulting & Communications Les Grèzes, La Verdarié, 81100 Castres, France; Tel/Fax: 33-563-59-735; E-mail:
Hide All
1.Wong DT, Bymaster FP, Engleman EA. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci. 1995;57:411441.
2.Beasley CM Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry. 1993;5:199207.
3.Cookson J. Side-effects of antidepressants. Br J Psychiatry Suppl. 1993;(20):2024.
4.Burrows GD, Maguire KP, Norman TR. Antidepressant efficacy and tolerability of the selective norepinephrine reuptake inhibitor reboxetine: a review. J Clin Psychiatry. 1998;59(Suppl 14):47.
5.Nelson JC. A review of the efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry. 1999;46:13011308.
6.Poston WS, Foreyt JP. Sibutramine and the management of obesity. Expert Opin Pharmacother. 2004;5:633642.
7.Millan MJ, Lejeune F, Gobert A. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol. 2000;14:114138.
8.Owens MJ. Selectivity of antidepressants: from the monoamine hypothesis of depression to the SSRI revolution and beyond. J Clin Psychiatry. 2004;65(Suppl 4):510.
9.Benveniste H, Huttemeier PC. Microdialysis—theory and application. Prog Neurobiol. 1990;35:195215.
10.Bymaster FP, Katner JS, Nelson DL, et al.Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699711.
11.Bymaster FP, Zhang W, Carter PA, et al.Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002;160:353361.
12.Wong DT, Bymaster FP. Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drag Res. 2002;58:169222.
13.Invemizzi RW, Garattini S. Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:819827.
14.Wikell C, Bergqvist PB, Hjorth S, Apelqvist G, Bjork H, Bengtsson F. Brain monoamine output alterations after a single venlafaxine challenge in experimental hepatic encephalopathy. Clin Neuropharmacol. 1998;21:296306.
15.Dawson LA, Nguyen HQ, Geiger A. Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. Neuropharmacology. 1999;38:11531163.
16.Koch S, Hemrick-Luecke SK, Thompson LK, et al.Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology. 2003;45:935944.
17.Vaishnavi SN, Nemeroff CB, Plott SJ, et al.Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry. 2004;55:320322.
18.Millan MJ, Gobert A, Lejeune F, et al.S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther. 2001;298:565580.
19.Weikop P, Kehr J, Scheel-Kruger J. The role of alphal- and alpha2-adrenoreceptors on venlafaxine-induced elevation of extracellular serotonin, noradrenaline and dopamine levels in the rat prefrontal cortex and hippocampus. J Psychopharmacol. 2004;18:395403.
20.Piacentini MF, Clinckers R, Meeusen R, Sarre S, Ebinger G, Michotte Y. Effects of venlafaxine on extracellular 5-HT, dopamine and noradrenaline in the hippocampus and on peripheral hormone concentrations in the rat in vivo. Life Sci. 2003;73:24332442.
21.Moret C, Marien M. Effects of venlafaxine on extracellular levels of 5-HT and noradrenaline in guinea pig hypothalamus. Society for Neuroscience Abstracts. 1997;23:1225. Abstract 485.5.
22.David DJ, Bourin M, Jego G, Przybylski C, Jolliet P, Gardier AM. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. Br J Pharmacol. 2003;140:11281136.
23.Mochizuki D, Tsujita R, Yamada S, et al.Neurochemical and behavioural characterization of milnacipran, a serotonin and noradrenaline reuptake inhibitor in rats. Psychopharmacology (Berl). 2002;162:323332.
24.Moret C, Briley M. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem. 1997;69:815822.
25.Kihara T, Ikeda M. Effects of duloxetine, a new serotonin and norepinephrine uptake inhibitor, on extracellular monoamine levels in rat frontal cortex. J Pharmacol Exp Ther. 1995;272:177183.
26.Gobert A, Rivet JM, Cistarelli JM, Millan MJ. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem. 1997;68:13261329.
27.Engleman EA, Perry KW, Mayle DA, Wong DT. Simultaneous increases of extracellular monoamines in microdialysates from hypothalamus of conscious rats by duloxetine, a dual serotonin and norepinephrine uptake inhibitor. Neuropsychopharmacology. 1995;12:287295.
28.Gur E, Dremencov E, Lerer B, Newman ME. Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur J Pharmacol. 1999;372:1724.
29.Bel N, Artigas F. Modulation of the extracellular 5-hydroxytryptamine brain concentrations by the serotonin and noradrenaline reuptake inhibitor, milnacipran. Microdialysis studies in rats. Neuropsychopharmacology. 1999;21:745754.
30.Felton TM, Kang TB, Hjorth S, Auerbach SB. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:297305.
31.Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503509.
32.Chalon SA, Granier LA, Vandenhende FR, et al.Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28:16851693.
33.Palmier C, Puozzo C, Lenehan T, et al.Monoamine uptake inhibition by plasma from healthy volunteers after single oral doses of the antidepressant, milnacipran. Eur J Clin Pharmacol. 1998;37:235238.
34.Turcotte JE, Debonnel G, de Montigny C, Hebert C, Blier P. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology. 2001;24:511521.
35.Vincent S, Bieck PR, Garland EM, et al.Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004;109:32023207.
36.Abdelmawla AH, Langley RW, Szabadi E, et al.Comparison of the effects of venlafaxine, desipramine, and paroxetine on noradrenaline- and methoxamine-evoked constriction of the dorsal hand vein. Br J Clin Pharmacol. 1999;48:345354.
37.Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol. 1996;11(Suppl 4):1527.
38.Troy SM, Parker VP, Hicks DR, Pollack GM, Chiang ST. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. J Clin Pharmacol. 1997;37:954961.
39.Lantz RJ, Gillespie TA, Rash TJ, et al.Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos. 2003;31:11421150.
40.Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol. 1996;41:149156.
41.Sawada Y, Ohtani H. Pharmacokinetics and drug interactions of antidepressive agents [Japanese]. Nippon Rinsho. 2001;59:15391545.
42.Perahia D, Pritchett YL, Lee TC, Tran PF. Comparing duloxetine and venlafaxine in the treatment of major depressive disorder using a global benefit-risk approach. Available at: Abstracts of NCDEU 2005; Poster 1-14.
43.Lopez-Ibor J, Guelfi JD, Pletan Y, Toumoux A, Prost JF. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol. 1996;11(Suppl 4):4146.
44.Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997;12:99108.
45.Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234241.
46.Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry. 2002;52:11661174.
47.Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol. 2004;24:389399.
48.Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull. 2001;57:161178.
49.Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl). 1986;90:131138.
50.Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord. 1990;18:289299.
51.Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol. 1994;8:238249.
52.Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr, Price LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a doubleblind, randomized study. Biol Psychiatry. 2004;55:296300.
53.Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180:396404.
54.Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs. 1995;49:280294.
55.Preskom SH. Antidepressant drug selection: criteria and options. J Clin Psychiatry. 1994;55(Suppl A):622.
56.Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9:139143.
57.Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:5771.
58.Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869877.
59.Nemeroff CB, Entsuah R, Willard LB, et al. Comprehensive pooled analysis of remission data: venlafaxine vs. SSRIs (COMPARE). Poster presented at: Annual Meeting of the American Psychiatric Association. May 17-22, 2003; San Francisco, Calif.
60.SirD'Souza R, George T, et al. Comparative efficacy of sertraline and venlafaxine XR in major depression. Poster presented at: Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
61.Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345350.
62.Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65:11901196.
63.Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004;50:5764.
65.Clerc G, Milnacipran/Fluvoxamine Study Group. Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine. Int Clin Psychopharmacol. 2001;16:145151.
64.Sechter D, Vandel P, Weiller E, et al.A comparative study of milnacipran and paroxetine in outpatients with major depression. J Affect Disord. 2004;83:233236.
66.Montes JM, Ferrando L, Saiz-Ruiz J. Remission in major depression with two antidepressant mechanisms: results from a naturalistic study. J Affect Disord. 2004;79:229234.
67.Detke MJ, Wiltse CG, Mallinckrodt CH, et al.Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004;14:457470.
68.Thase ME, Lu Y, Joliat MJ, et al. Remission in placebo-controlled trials of duloxetine with an SSRI comparator. Poster presented at: Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif.
69.Duloxetine product information. Cymbalta Web site. Available at: Accessed on June 1, 2005.
70.Kessler RC, McGonagle KA, Zhao S, et al.Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:819.
71.Silverstone PH. Qualitative review of SNRIs in anxiety. J Clin Psychiatry. 2004;65(Suppl 17):1928.
72.Tanaka M, Yoshida M, Emoto H, Ishii H. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol. 2000;405:397406.
73.Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety. 2000;12(Suppl 1):219.
74.Iny LJ, Pecknold J, Suranyi-Cadotte BE, et al.Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry. 1994;36:281291.
75.Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry. 2002;63(Suppl 8):1723.
76.Pollack MH, Zaninelli R, Goddard A, et al.Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001;62:350357
77.Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997;95:444450.
78.Feldman S, Weidenfeld J. The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41. Brain Res Bull. 1998;45:389393.
79.Sevy S, Papadimitriou GN, Surmont DW, Goldman S, Mendlewicz J. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry. 1989;25:141152.
80.Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am J Psychiatry. 2000;157:968974.
81.Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000;283:30823088.
82.Davidson JR, DuPont RL, Hedges D, et al.Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60:528535.
83.Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry. 2003;18:182187.
84.Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry. 2001;179:1522.
85.Allgulander C, Mangano R, Zhang J, et al.Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol. 2004;19:387396.
86.Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24:488496.
87.Liebowitz MR, Mangano RM, Bradwejn J, Asnis G; SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005;66:238247.
88.Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62:190198.
89.Whitaker T, Bradwejn J, Emilien G, et al. Treatment of panic disorder with venlafaxine XR. Poster presented at: Annual Meeting of the American College of Neuropsychopharmacology; December 7-11, 2003; San Juan, PR.
90.Pollack MH, Emilien G, Tzanis E, et al. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Poster presented at: Annual Meeting of the World Federation for the Society of Biological Psychiatry; February 6-13, 2004; Sydney, Australia.
91.Liebowitz MR, Asnis G, Tzanis E, et al. A placebo-controlled trial of venlafaxine XR in the short-term treatment of panic disorder. Poster presented at: Annual Meeting of the Collegium Internationale Neuropsychopharmacologicum; June 20-24, 2004; Paris, France.
92.Davidson J, Lipschitz A, Musgnung J. A double-blind comparison of venlafaxine XR, sertraline, and placebo in the treatment of PTSD. Poster presented at: Annual meeting of the New Clinical Drug Evaluation Unit; June 1-4, 2004; Phoenix, Ariz.
93.Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23:568575.
94.Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety. 2002;16:413.
95.Tsukamoto T, Kondoh R, Ichikawa K. Efficacy and safety of milnacipran in the treatment of generalized anxiety disorder: an open study. Int J Psychiatry Clin Pract. 2004;8:255258
96.Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety. 2003;18:5361.
97.Stahl SM. Does depression hurt? J Clin Psychiatry. 2002;63:273274.
98.Briley M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs. 2003;4:4245.
99.Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum Psychopharmacol. 2004(19 Suppl 1):S21S25.
100.Delgado PL. Common pathways of depression and pain. J Clin Psychiatry. 2004;65 (Suppl 12):1619.
101.Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med. 2000;1:310316.
102.Entsuah AR. Venlafaxine vs SSRIs: comparison of somatic symptom resolution. World J Biol Psychiatry. 2004;5(Suppl 1):9297.
103.Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 1992;326:12501256.
104.Max MB. Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol. 1994;35(Suppl):S50S53.
105.Staiger TO, Gaster B, Sullivan MD, Deyo RA. Systematic review of antidepressants in the treatment of chronic low back pain. Spine. 2003;28:25402545.106.
Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother. 2003;7:15611565.
107.Sumpton JE, Moulin DE. Treatment of neuropathic pain with venlafaxine. Ann Pharmacother. 2001;35:557559.
108.Sindrup SH, Bach FW, Madsen C, Gram LF, Jensen TS. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology. 2003;60:12841289.
109.Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. Eur J Pain. 2002;6:1724.
110.Vitton O, Gendreau M, Gendreau J. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol. 2004;19(Suppl 1):S27S35.
111.Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308315.
112.Brannan SK, Mallinckrodt CH, Detke MJ, Watkin JG, Tollefson GD. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res. 2005;39:161172.
113.Arnold LM, Lu Y, Crofford LJ, et al.A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50:29742984.
114.Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61:445449.
115.Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia—a randomized, double-blind, placebo-controlled study. Eur J Pain. 2000;4:2735.
116.Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr.A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112:191197.
117.O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract. 1999;48:980990.
118.O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med. 2000;15:659666.
119.Aragona M, Bancheri L, Perinelli D, et al.Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder. Eur J Pain. 2005;9:3338.
120.Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs. 2001;15:643669.
121.Raskin J, Goldstein DJ, Mallinckrodt CH, Ferguson MB. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry. 2003;64:12371244.
122.Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19:6785.
123.Keltner NL, McAfee KM, Taylor CL. Mechanisms and treatments of SSRI-induced sexual dysfunction. Perspect Psychiatr Care. 2002;38:111116.
124.Clayton AH, Pradko JF, Croft HA, et al.Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002;63:357366.
125.Deakin B, Dursun S. Optimizing antidepressant treatment: efficacy and tolerability. Int Clin Psychopharmacol. 2002;17(Suppl 1):S13S24.
126.McGahuey CA, Gelenberg AJ, Laukes CA, et al.The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:2540.
127.Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25:255261.
128.Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol. 2002;17:217225.
129.Michelson D, Fava M, Amsterdam J, et al.Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363368.
130.Pinzani V, Ginies E, Robert L, Peyriere H, Abbar M, Blayac JP. Venlafaxine withdrawal syndrome: report of six cases and review of the literature [French]. Rev Med Interne. 2000;21:282284.
131.Trenque T, Piednoir D, Frances C, et al.Reports of withdrawal syndrome with the use of SSRIs: a case/non-case study in the French Pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2002;11:281283.
132.Vandel P, Sechter D, Weiller , et al.Post-treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol. 2004;19:585586.
133.Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry. 1995;56:574579.
134.Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502508.
135.Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1999;291:280284.
136.Combes A, Peytavin G, Theron D. Conduction disturbances associated with venlafaxine. Ann Intern Med. 2001;134:166167.
137.Committee for the Safety of Medicines page. Medicine and Healthcare Products Regulatory Agency Web site. Available at: Accessed on December 13, 2004.
138.Guelfi JD, Ansseau M, Corruble E, et al.A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients. Int Clin Psychopharmacol. 1998;13:121128.
139.Montgomery SA, Prost JF, Solles A, Briley M. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 1996;11(Suppl 4):4751.
140.Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64(Suppl 13):3037.
141.Thase ME, Tran PV, Wiltse C, Pangallo BA, Mallinckrodt C, Detke MJ. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol. 2005;25:132140.
142.Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ. 1995;310:215218.
143.Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry. 1998;59(Suppl 15):4248.
144.Isbister GK, Bowe SJ, Dawson A, et al.Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004;42:277285.
145.Dams R, Benijts TH, Lambert WE, et al.A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J Anal Toxicol. 2001;25:147151.
146.Schweizer E, Feighner J, Mandos LA, et al.Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry. 1994;55:104108.
147.Ereshefsky L. Drug-drug interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol. 1996;16(Suppl 2):37S53S.
148.Settle EC Jr.Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry. 1998;59(Suppl 16):2530.
149.Mazur JE, Doty JD, Krygiel AS. Fatality related to a 30-g venlafaxine overdose. Pharmacotherapy. 2003;23:16681672.
150.Kelly CA, Dhaun N, Laing WJ, et al.Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol. 2004;42:6771.
151.Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ. 2002;325:13321333.
152.Cheeta S, Schifano F, Oyefeso A, et al.Antidepressant-related deaths and antidepressant prescriptions in England and Wales, 1998-2000. Br J Psychiatry. 2004;184:4147.
153.Medicine and Healthcare Products Regulatory Agency Web site. Available at: Accessed on December 13, 2004.
154.Thompson C. Mirtazapine versus selective serotonin reuptake inhibitors. J Clin Psychiatry. 1999;60(Suppl 17):1822
155.Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):59.
156.Paykel ES, Ramana R, Cooper Z, et al.Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25:11711180.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 1
Total number of PDF views: 215 *
Loading metrics...

Abstract views

Total abstract views: 1888 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 23rd November 2017. This data will be updated every 24 hours.